Production (Stage)
Capricor Therapeutics, Inc.
CAPR
$12.38
$0.605.09%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | 392.15% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | 392.15% | |||
| Cost of Revenue | 29.96% | 23.26% | |||
| Gross Profit | -452.38% | 64.13% | |||
| SG&A Expenses | 41.98% | 23.38% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 32.69% | 23.29% | |||
| Operating Income | -224.55% | 40.83% | |||
| Income Before Tax | -242.74% | 43.32% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -242.74% | 43.32% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -242.74% | 43.32% | |||
| EBIT | -224.55% | 40.83% | |||
| EBITDA | -235.66% | 42.11% | |||
| EPS Basic | -234.27% | 57.87% | |||
| Normalized Basic EPS | -237.74% | 58.56% | |||
| EPS Diluted | -234.27% | 57.87% | |||
| Normalized Diluted EPS | -237.74% | 58.56% | |||
| Average Basic Shares Outstanding | 2.53% | 34.51% | |||
| Average Diluted Shares Outstanding | 2.53% | 34.51% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||